Abstract
MicroRNAs (miRNAs) are a class of post-transcriptional gene expression modulators. In the past two decades, over 1500 human miRNAs were discovered. These small non-coding RNAs regulate various biological processes, including cell growth, proliferation, differentiation, and cell death. Thus, miRNAs have been proposed as new therapeutical agents in different multifactorial diseases such as cancer. Since miRNAs therapies represent a great promise, many research studies have been focused on the development of delivery strategies to overcome miRNAs biopharmaceutical issues. Lipid delivery systems are undoubtedly the non-viral carriers most largely investigated due to their biocompatibility, biodegradability, easy production, low toxicity and immunogenicity, possibility to easily modify the carriers for targeting strategies. In this mini-review we provide a rapid and updated overview on the lipid delivery system currently used to deliver miRNAs, pointing out the progresses achieved in the optimization of these nanovectors, which led up to the first clinical trial.
Keywords: microRNAs; miRNA delivery, nanocarriers; lipid-based delivery systems; liposomes, SNALPs, solid lipid nanoparticles, nanoemulsions, drug targeting.
Current Pharmaceutical Biotechnology
Title:Lipid Nanoparticles to Deliver miRNA in Cancer
Volume: 17 Issue: 8
Author(s): Virginia Campani, Giuseppe De Rosa, Gabriella Misso, Mayra R. Zarone and Anna Grimaldi
Affiliation:
Keywords: microRNAs; miRNA delivery, nanocarriers; lipid-based delivery systems; liposomes, SNALPs, solid lipid nanoparticles, nanoemulsions, drug targeting.
Abstract: MicroRNAs (miRNAs) are a class of post-transcriptional gene expression modulators. In the past two decades, over 1500 human miRNAs were discovered. These small non-coding RNAs regulate various biological processes, including cell growth, proliferation, differentiation, and cell death. Thus, miRNAs have been proposed as new therapeutical agents in different multifactorial diseases such as cancer. Since miRNAs therapies represent a great promise, many research studies have been focused on the development of delivery strategies to overcome miRNAs biopharmaceutical issues. Lipid delivery systems are undoubtedly the non-viral carriers most largely investigated due to their biocompatibility, biodegradability, easy production, low toxicity and immunogenicity, possibility to easily modify the carriers for targeting strategies. In this mini-review we provide a rapid and updated overview on the lipid delivery system currently used to deliver miRNAs, pointing out the progresses achieved in the optimization of these nanovectors, which led up to the first clinical trial.
Export Options
About this article
Cite this article as:
Campani Virginia, De Rosa Giuseppe, Misso Gabriella, R. Zarone Mayra and Grimaldi Anna, Lipid Nanoparticles to Deliver miRNA in Cancer, Current Pharmaceutical Biotechnology 2016; 17 (8) . https://dx.doi.org/10.2174/138920101708160517234941
DOI https://dx.doi.org/10.2174/138920101708160517234941 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Correlation between Cancer Antigen 15.3 Value and Qualitative and Semiquantitative Parameters of Positron Emission Tomography/Computed Tomography in Breast Cancer Patients
Current Radiopharmaceuticals Anti-Helicobacter pylori Agents. An Update
Mini-Reviews in Medicinal Chemistry Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets Interventional Radiology in Paediatrics
Current Pediatric Reviews Bronchial Thermoplasty: Burn to Cure?
Current Respiratory Medicine Reviews Domperidone and Long QT Syndrome
Current Drug Safety Herpes Simplex Encephalitis: From Virus to Therapy
Infectious Disorders - Drug Targets Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Atopic Dermatitis and Cytokines: Recent Patents in Immunoregulatory and Therapeutic Implications of Cytokines in Atopic Dermatitis - Part I: Cytokines in Atopic Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design Ribosomal Proteins and Colorectal Cancer
Current Genomics The Synergistic Cytotoxic and Apoptotic Effect of Resveratrol and Naringenin on Y79 Retinoblastoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy
Current Cancer Drug Targets Clonetics
Current Drug Metabolism Clinical Impacts of Juxtapapillary Duodenal Diverticulum Detected on Computed Tomography
Current Medical Imaging Inhibition of Cyclin-Dependent Kinases - A Review of the Recent Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology Postoperative Thoracic Epidural Anesthesia in Gastrointestinal Surgery: Outcomes, Quality of Life, and Current Controversies
Current Drug Therapy